Prenatal Exposure to Air Pollutants Associated with Allergic Diseases in Children: Which Pollutant, When Exposure, and What Disease? A Systematic Review and Meta-analysis
AbstractThis systematic review aims to identify the association between prenatal exposure to air pollutants and allergic diseases in children, focusing on specific pollutants, timing of exposure, and associated diseases. We searched PubMed, Scopus, and Web of Science for English articles until May 1, 2023, examining maternal exposure to outdoor air pollutants (PM1, PM2.5, PM10, NO, NO2, SO2, CO, and O3) during pregnancy and child allergic diseases (atopic dermatitis (AD), food allergy (FA), asthma (AT) and allergic rhinitis (AR)/hay fever (HF)). The final 38 eligible studies were included in the meta-analysis. Exposure ...
Source: Clinical Reviews in Allergy and Immunology - April 19, 2024 Category: Allergy & Immunology Source Type: research
Sociodemographic factors linked to food allergy diagnosis among high-risk children with atopic dermatitis
Atopic dermatitis (AD) is a known risk factor for the development of food allergy. Prior work has suggested disparities in diagnosis/management of food allergy in urban populations. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 19, 2024 Category: Allergy & Immunology Authors: Ellen Daily Stephen, Sven Wang, Manali Shah, Anandu Dileep, Shannon Manz, Niki Mirhosseini, Mahboobeh Mahdavinia Source Type: research
Tolerance induction through early feeding to prevent food allergy in infants and children with sensitization against food allergens (TIFFANI): rationale, study design, and methods of a randomized controlled trial
Children with sensitization against foods have to be orally food-challenged before eating these foods for the first time. However, the waiting time for an oral food challenge (OFC) in Germany is about 3 –6 mont... (Source: Trials)
Source: Trials - April 19, 2024 Category: General Medicine Authors: Birgit Kalb, Lara Meixner, Stephanie Heller, Sabine D ölle-Bierke, Stephanie Roll, Tatjana Tissen-Diabaté, Susanne Lau, Sofia Forslund, Ingo Marenholz, Young-Ae Lee, Andreas Thiel, Magda Babina, Jörg Scheffel, Margitta Worm and Kirsten Beyer Tags: Study protocol Source Type: research
The OUtMATCH study: treating multiple allergies
It is recognised that of those children who do have allergies (about 8% of the population), 30–80% have responses to multiple foods. A double blind, placebo-controlled, randomised clinical trial, the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food Allergic Participants (OUtMATCH) study is a three phase study comparing omalizumab to placebo in children with multiple food allergies and is in its first phase. The study then goes on to phase two, a longer-term (52 weeks) treatment with omalizumab with oral immunotherapy and then the third stage will assess the introduction of...
Source: Archives of Disease in Childhood - April 18, 2024 Category: Pediatrics Tags: Miscellanea Source Type: research
Gut microbiota: A target for prebiotics and probiotics in the intervention and therapy of food allergy
(Source: Critical Reviews in Food Science and Nutrition)
Source: Critical Reviews in Food Science and Nutrition - April 10, 2024 Category: Nutrition Authors: Bai, Jing Zhao, Xiaoli Zhang, Maolin Xia, Xinlei Yang, Anshu Chen, Hongbing Source Type: research
Basophil activation test in the food allergy clinic: its use current use and future applications
Expert Rev Clin Immunol. 2024 Apr 9. doi: 10.1080/1744666X.2024.2336568. Online ahead of print.ABSTRACTThe basophil activation test (BAT) has shown evidence of high sensitivity and high specificity to support the diagnosis of IgE-mediated allergy. It is a functional test that uses live cells analyzed by flow cytometry and thus needs to be performed within 24 h of blood collection. BAT has shown to be reproducible and reliable when tested in a clinical diagnostic laboratory with standardized protocols and flow cytometry settings. BAT has recently been included in Clinical Guidelines of Food Allergy Diagnosis and its impleme...
Source: Expert Review of Clinical Immunology - April 9, 2024 Category: Allergy & Immunology Authors: Marcel M Bergmann Alexandra F Santos Source Type: research
Basophil activation test in the food allergy clinic: its current use and future applications
Expert Rev Clin Immunol. 2024 Apr 10:1-8. doi: 10.1080/1744666X.2024.2336568. Online ahead of print.ABSTRACTINTRODUCTION: The basophil activation test (BAT) has shown evidence of high sensitivity and high specificity to support the diagnosis of IgE-mediated allergy. It is a functional test that uses live cells analyzed by flow cytometry and thus needs to be performed within 24h of blood collection. BAT has shown to be reproducible and reliable when tested in a clinical diagnostic laboratory with standardized protocols and flow cytometry settings.AREAS COVERED: In this review, we summarize the evidence to support clinical u...
Source: Expert Review of Clinical Immunology - April 9, 2024 Category: Allergy & Immunology Authors: Marcel M Bergmann Alexandra F Santos Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
